Press Releases for GENZ

Press Releases
Targeted Genetics Corporation Reports Third Quarter 2009 Financial Results
Drug company warns of contamination
Dyadic International Reports Financial Results for First and Second Quarters of 2009 and Fiscal Years 2008 and 2007
Genzyme Reports Third-Quarter Financial Results
Windhover Brings Roche, Genentech Executives Together to Talk Business Development
Genzyme Named to Dow Jones Sustainability World and North American Indexes
Holzer Holzer & Fistel, LLC Announces That a Class Action Lawsuit Has Been Filed on Behalf of Investors in Genzyme Corp.
BenchmarkJournal.Com Free Analyst Review for ENER, GENZ, DLTR, IDTI, COST and EGLE
StockPreacher.com Issues Trading Outlook for Nabi Biopharmaceuticals
Exact Sciences Reports Second-Quarter 2009 Financial Results
Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
StockPreacher.Com Issues Trading Outlook for Keryx Biopharmaceuticals Inc.
Brower Piven Encourages Investors Who Have Losses in Excess of $200,000 From Investment in Genzyme Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the September 28, 2009 Lead Plaintiff Deadline
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Genzyme Corporation
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
European Commission Approves Genzyme’s Mozobil
Hagens Berman Announces Class-Action Lawsuit Filed Against Genzyme Corporation
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Genzyme Corporation, Announces Class Action Lawsuit and Seeks to Recover Losses
The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Genzyme Corp.
Izard Nobel LLP Announces Class Action Lawsuit Against Genzyme Corporation
Genzyme Provides Update on Allston Landing Plant
Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Genzyme Corp. (NASDAQ: GENZ)
Kendall Law Group Announces Class Action Against Genzyme Corporation
Gardy & Notis, LLP Files Securities Fraud Class Action Against Genzyme Corporation -- GENZ
Genzyme Delivers Solid Second-Quarter Financial Results
Drug maker begins cleanup to kill virus
Virus pushes drug maker to halt production
Genzyme Reports Progress Related to Allston Plant
MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination
Genzyme halts drug production amid scare
Genzyme Temporarily Interrupts Production at Allston Plant
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
Battle Road Research Expands Healthcare Coverage and Launches Blog
Genzyme Completes Transaction with Bayer HealthCare
Genzyme Receives Positive Opinion for European Approval of Mozobil
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Genzyme Submits All Information Requested by FDA for Lumizyme
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals
Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting
Genzyme Reports Solid Financial Results for the First Quarter of 2009
Genzyme Takes Bayer to Relieve Headache of Entering Seattle Biotech Hub, an Industrial Info News Alert
Impax Confirms Patent Challenge Relating to Renvela® 800 Mg Tablets
Genzyme and Bayer HealthCare Enter New Strategic Agreement
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Avigen Board Discontinues Strategic Merger Discussions to Develop a Plan for Liquidation; Avigen Board Neutral On Tender Offer
Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
Impax Confirms Patent Challenge Relating to RENAGEL(R) Tablets, 400 Mg and 800 Mg
Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
FDA Approves Genzyme’s Synvisc-One for Osteoarthritis of the Knee
Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint
Genzyme Receives Positive Opinion on Myozyme from CHMP
Zacks Analyst Blog Highlights: TriQuint Semiconductor, MGIC Investment Corp., Embotelladora Andina S.A., Osiris Therapeutics and Genzyme
Strong Fourth Quarter for Genzyme Concludes Productive Year
Genzyme Center Wins Prestigious Architecture Award
QRxPharma Expands Management Team With the Addition of Dr. Jesus Soriano As Executive Vice President
Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth
Genzyme and Isis Begin New Clinical Trials of Mipomersen
Genzyme to Present at 27th Annual JPMorgan Healthcare Conference
BenchmarkJournal.Com (Complimentary) Analyst Review for JASO, BIDU, TEVA and GENZ
FDA Approves Genzyme’s Mozobil
Progress by Genzyme, the Broad Institute and Medicines for Malaria Ventures Toward Developing Drug Candidates for Malaria Highlighted at Tropical Medicine Meeting
FDA Advisory Committee Unanimously Recommends Approval of Genzyme’s Synvisc-One
Genzyme Reports Clolar® Data Further Supporting Potential of Product to Treat Adult AML Patients
FDA Advisory Committee to Discuss Genzyme’s Synvisc-One PMA on Tuesday
Genzyme Seeks U.S. Approval for Clolar® to Treat Adult AML
Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases
Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
Zacks Analyst Blog Highlights: CDC Corp., Isis Pharmaceuticals, Inc., Genzyme Corp., Priceline.Com and American Oil & Gas, Inc.
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
Zacks #1 Rank Top Performers: Matrix Service, Allegiant Travel, Genzyme, Genesee & Wyoming and Knoll
Genzyme Reports Strong Third-Quarter Sales and Earnings Growth
Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
FDA Advisory Panel to Discuss Genzyme's Myozyme BLA on Tuesday
Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
Genzyme Recognized by Scientists as a Top Employer
Genzyme Provides Details of October Myozyme (alglucosidase alfa) Advisory Panel Meeting and Additional Regulatory Updates
Seven Summits Research Releases Alerts on WFC, CSCO, HD, VLO, and GENZ
Genzyme Marks Grand Opening of New Science Center; Among the First Research Laboratories to Earn Gold LEED Rating
BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
Genzyme Reports Strong Second-Quarter Growth
Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
Genzyme and Isis Complete Licensing of Mipomersen
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
Seven Summits Research Releases Alerts on INTC, DIS, NMX, GENZ, and DFS
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction - May 27 2008 12:42AM
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, HealthShares(TM) Dermatology and Wound Care Index and HealthShares(TM) Orthopedic Repair Index - May 27 2008 12:42AM
Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease - Jun 3 2008 3:14AM
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Genzyme Reports Strong First-Quarter Growth
Genzyme to Build New R&D Center in Beijing
Genzyme Provides Update on Myozyme(R) Manufacturing
Seven Summits Research Releases Alerts on RIMM, C, MA, JOYG, and GENZ